tbuckley/cabot-search huggingface dataset:
Abstract 903: Low Plasma Adiponectin Level and High Oxidative Stress are Associated with In Vivo Thin-Cap Fibroatheloma Prevalence in Patients with Stable Coronary Artery Disease
Authors: Takahiro Sawada, Junya Shite, Toshiro Shinke, Yusuke Tanino, Daisuke Ogasawara, Hiroyuki Kawamori, Hiroki Kato, Naoki Miyoshi, Naoki Yoshino, Ken-ichi Hirata
Journal: Circulation (2008)

Background ; Few studies have investigated the association between biomarkers and in vivo plaque vulnerability in patients with stable coronary artery disease (CAD). Methods ; We examined two or three vessels of 55 stable CAD patients with combined use of virtual histology intravascular ultrasound (VH-IVUS) and optical coherence tomography (OCT), and diagnosed thin-cap fibroatheroma (TCFA). The definition of TCFA was described as follow: necrotic core rich lesion (%necrotic-core&gt;10%) without evident overlying fibrous component and %plaque-volume&gt;40% by VH-IVUS analysis, and the thinnest fibrous-cap thickness &lt;65μm by OCT measurement. The patients were divided into two groups, the patients with TCFA and without TCFA, and compared their clinical characteristics, laboratory data and new atherosclerotic biomarkers (adiponectin, oxidative stress marker) between these two groups. Results ; In 55 patients, we could observe 126 vessels (2.29±0.46 vessel/patient) with both modality and we identified 37 TCFA in them. At least one TCFA was identified in 24 patients (43.6%) and not in 31 patients. There were no differences in the clinical characteristics between the two groups. However, a greater number of patients with TCFA had a past history of ACS than those without TCFA (P=0.04). As for laboratory data, there were no differences in lipid and sugar profiles and inflammatory markers, but patients with TCFA had lower plasma adiponectin levels and higher urine- 8-isoprostane/creatinine levels, which is considered as reliable in vivo oxidative stress marker, than patients without TCFA (p=0.0002, P=0.04, respectively). Multivariate logistic regression analysis revealed the most powerful indicative factor of TCFA prevalence in stable CAD was plasma adiponectin levels (P=0.001). The receiver-operating characteristic curve analysis identified plasma adiponectin &lt;6.8μg/ml (Area under curve = 0.80, 95% confidence interval = 0.67 to 0.90, P=0.0001, sensitivity 70.8%, specificity 80.6%) as the optimal cut-off point for prediction of the TCFA prevalence in stable CAD. Conclusion ; Plasma adiponectin levels and urine-8-isoprostane may be one of the tools that help to stratify vulnerable patients into risk categories in patients with stable CAD.
Liver and pancreatic fat content and metabolism in healthy monozygotic twins with discordant physical activity
Authors: Jarna C Hannukainen, Ronald Borra, Kaisa Linderborg, Heikki Kallio, Jan Kiss, Virva Lepomäki, Kari K. Kalliokoski, Urho M. Kujala, Jaakko Kaprio, Olli J. Heinonen, Markku Komu, Riitta Parkkola, Markku Ahotupa, Terho Lehtimäki, Risto Huupponen, Patricia Iozzo, Pirjo Nuutila
Journal: Journal of Hepatology (2010)
Fortnightly Review: Management of acoustic neuroma
Authors: A Wright, R Bradford
Journal: BMJ (1995)

Thank you for your interest in spreading the word about The BMJ.NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Username * Your Email * Send To * You are going to email the following Fortnightly Review: Management of acoustic neuroma Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans Is Associated With Nonalcoholic Fatty Liver Disease
Authors: Sahil Mittal, Hashem B. El-Serag, Yvonne H. Sada, Fasiha Kanwal, Zhigang Duan, Sarah Temple, Sarah B. May, Jennifer R. Kramer, Peter A. Richardson, Jessica A. Davila
Journal: Clinical Gastroenterology and Hepatology (2015)
Correlation of clinical response to BMS-354825 with BCR-ABL mutation status in imatinib-resistant patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-associated acute lymphoblastic leukemia (Ph+ ALL)
Authors: N. Shah, C. L. Sawyers, H. M. M. Kantarjian, N. Donato, J. Nicoll, J. Cortes, R. Paquette, F. Huang, E. Clark, M. Talpaz
Journal: Journal of Clinical Oncology (2005)

6521 Background: Relapse of CML on imatinib is most often associated with point mutations in the BCR-ABL kinase domain. BMS-354825 is a novel ABL kinase inhibitor with ≥ 300-fold greater potency than imatinib and preclinical activity against 14 of 15 imatinib resistant BCR-ABL mutants tested. Unlike imatinib, BMS-354825 binds the ABL kinase domain in both active and inactive conformations, and is thus predicted to have significant activity in most imatinib-resistant CML and Ph+ ALL cases. Methods: CA180002 is a phase I, dose-escalation study in CML and Ph+ ALL patients resistant or intolerant to imatinib. Prior to therapy, peripheral blood samples were collected for mutation analysis for correlation with response. Response was assessed by standard methods. Sixty-three patients are currently evaluable [chronic phase=36, accelerated phase=8, blast phase/Ph+ ALL=19]. Results: Seventeen different imatinib-resistant point mutations in the BCR-ABL kinase domain were identified in 67% of patients prior to therapy. Complete hematologic remission has been observed in patients harboring each of these mutations except T315I (5), F317L (1), and D276G (1). The two patients with F317L and D276G have had partial responses and remain on study. The T315I mutation is highly resistant to BMS-354825 in experimental systems. Nine patients have gone off study due to progressive disease. Of these, three had T315I detected prior to treatment and two patients had the T315I mutation at the time of disease progression. Assessment of BCR-ABL kinase inhibition by analysis of phospho-CRKL in patient samples was correlated with response, and loss of BCR-ABL kinase inhibition was correlated with relapse. Conclusions: Clinical activity of BMS-354825 in imatinib-resistant CML and Ph+ ALL is observed in patients with a wide range of imatinib-resistant BCR-ABL kinase domain mutations. The exception to date is T315I, which is cross-resistant to both drugs, as predicted from preclinical studies. This works demonstrates the utility of molecular assessment of tumor early in the clinical evaluation of a targeted inhibitor. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Bristol-Myers Squibb Bristol-Myers Squibb Bristol-Myers Squibb Bristol-Myers Squibb Bristol-Myers Squibb
Abstract 5857: Low Operative Mortality with implantation of a Continuous Flow LVAD and Impact of Concurrent Cardiac Procedures
Authors: Jay D Pal, Charles T Klodell, Ranjit John, Francis Pagani, Joseph G Rogers, David J Farrar, Carmelo A Milano
Journal: Circulation (2008)

Objective: Our goal was to determine the operative mortality of isolated implantation of the HeartMate II continuous flow LVAD and the impact of additional concurrent cardiac procedures on patient outcomes. Methods: In a multicenter trial, 279 patients at 33 clinical sites underwent implantation of the HeartMate II continuous flow LVAD as a bridge to transplantation from March 2005 to March 2007. HeartMate II implantation (HM II) was the only procedure required in 172 patients while 80 patients required concurrent cardiac procedures in conjunction with LVAD implantation (HM II+CCP). Results: Preoperative characteristics were similar, but central venous pressure (14.5 vs 11.6 mmHg) was greater for patients requiring concurrent cardiac procedures, suggesting worse right heart dysfunction. Mean cardiopulmonary bypass times increased from 97 to 120 minutes when a concurrent cardiac procedure was performed (p&lt;0.001). Length of stay slightly increased from 23 to 26 days (p=0.17). Overall 30- and 180-day mortality was 5.8% and 13.3% for the HM II group, and 11.3% and 20.0% for the HM II+CCP group. Concurrent valvular procedures increased the risk to 8.5% and 19.1%. Patients who underwent an aortic valve replacement with cardioplegic arrest had a 30-day mortality of 25%, higher than for isolated concurrent mitral (0%) or tricuspid repair (3.3%). Other cardiac procedures were associated with a 30-day mortality of 27.8%. Survival at 180 days was 87% for HMII alone and 80% for HMII+CCP. Conclusion: There is a low 5.8% operative mortality for patients requiring uncomplicated HeartMate II implantation, with no apparent increased risk for concurrent PFO closure, mitral or tricuspid repair. However, concurrent aortic valve and other cardiac procedures are associated with a significantly decreased survival. The increased risk of these procedures must be balanced against the negative impact of uncorrected aortic insufficiency during VAD support.
Prognostic Significance of Anaplastic Lymphoma Kinase (ALK) Protein Expression in Adults With Anaplastic Large Cell Lymphoma
Authors: Randy D. Gascoyne, Patricia Aoun, Daniel Wu, Mukesh Chhanabhai, Brian F. Skinnider, Timothy C. Greiner, Stephan W. Morris, Joseph M. Connors, Julie M. Vose, David S. Viswanatha, Andrew Coldman, Dennis D. Weisenburger
Journal: Blood (1999)
Late-breaking abstract: Burden and risk factors of chronic bronchitis - results from the Burden of Obstructive Lung Disease (BOLD) Study
Authors: Filip Mejza, Daniel Obaseki, Louisa Gnatiuc, Sonia Buist, William Vollmer, Bernd Lamprecht, Pawel Nastalek, Ewa Nizankowska-Mogilnicka, Krzysztof Sladek, Peter Burney
Journal: European Respiratory Journal (2014)

Introduction 

The BOLD Study is an international study aimed to describe prevalence and burden of COPD across different parts of the world.

Methods 

Representative population-based samples of adults aged 40+ have been randomly selected in participating sites. Participants underwent questionnaire and pre- and post –bronchodilator spirometry. Chronic bronchitis (CB) was defined as chronic cough and phlegm on most days for ≥3 months each year for ≥2 years.

Results 

16,201 subjects from 23 sites were analyzed. CB was reported by 2.9% (95%CI: 2.3-3.4); 2.0% (95%CI: 1.6 – 2.4) in those without COPD and 11.5% (95% CI: 7.3-15.7) in those with COPD. CB prevalence varied across study sites (fig. 1).

![Figure][1] 



In the multivariate analyses the presence of CB was related with increased prevalence of respiratory symptoms, dyspnoea, breathing problems interfering with daily activities and reduced quality of life. Smoking, family history of chronic lung disease, and childhood lung disease were related with increased CB risk (fig. 2).

![Figure][1]  [1]: pending:yes
Abstract 12958: Betablocker Use in Patients with Chronic Pulmonary Disease During Acute Phase of Myocardial Infarction. Insights from Euro Heart Survey Acute Coronary Syndromes III
Authors: Francois Schiele, Hector Bueno, Matthias Hochadel, Marco Tubaro, Nicolas Meneveau, Wojtek Wojakowski, Marek Gierlotka, Jean-Pierre Bassand, Keith A Fox, Anselm K Gitt
Journal: Circulation (2012)
Nanostructure Processing of Advanced Biomaterials and Biosystems
Authors: Jackie Yi-Ru Ying
Journal: Clinical Cancer Research (2007)

AACR Centennial Conference: Translational Cancer Medicine-- Nov 4-8, 2007; Singapore

PL01-03 

Nanostructured materials have been designed for the controlled delivery of drugs, proteins and genes. These materials can be engineered for targeting specific cell types, and with responsiveness to selected stimuli. The intelligent delivery systems provide for greater efficiency and reduced side-effects for treatment of various diseases, including cancer.    Fluorescent quantum dots have been subjected to thin glutathione or silane coating to render them water-soluble, buffer-stable and non-cytotoxic for biological applications. They are further bioconjugated to target specific cell types and compartments for biolabeling and bioimaging applications. We have also derived novel nanocomposites of quantum dots and magnetic nanoparticles to create multifunctional systems for imaging, bioseparation and targeted delivery applications. These materials are of particular interest for cancer and stem cell research.    Miniaturized biological and medical devices have been fabricated with microfluidic control for drug screening and medical diagnostic applications. They allow for accurate and high-speed studies and detections involving small sample volumes. Such systems are being developed specifically cancer and infectious disease research.
Abstract 2762: Reproducibility and Reliability of Atherosclerotic Plaque Imaging in Peripheral Arterial Disease: Implications for Clinical Trials
Authors: David C Isbell, Justin D Anderson, Craig H Meyer, Walter J Rogers, Hongkun Wang, Frederick H Epstein, Nancy L Hartun, Christopher M Kramer
Journal: Circulation (2006)

Introduction: Measurement of atherosclerotic plaque volume (APV) in the superficial femoral artery (SFA) by magnetic resonance imaging (MRI) may allow reduced sample sizes for studies of serial cha...
Abstract 6054: Immersing Feet in CO <sub>2</sub> -Rich Water-Bath Improves Ulcer Healing on Ischemic Limb after Infrainguinal Bypass Surgery
Authors: Hisae Hayashi, Yoshitaka Kumada, Kyuichi Furuhashi, Hiroshi Takahashi, Takanobu Toriyama, Hideki Ishii, Sumio Yamada, Toyoaki Murohara
Journal: Circulation (2008)

Background : We have shown that immersion of feet in warmed water enriched with carbon dioxide (CO 2 immersion) improves subcutaneous microcirculation in critical limb ischemia (CLI) with ischemic ulcer/gangrene. Using an animal model, other group has reported that the CO 2 immersion enhances collateral blood flow in ischemic limb via mobilization of endothelial progenitor cells and activation of NO-cGMP system. For CLI patients with ulcer/gangrene, infrainguinal bypass surgery is the standard therapy. However, ulcer healing and prevention of amputation still remain suboptimal. In order to know whether the CO 2 immersion improves the clinical efficacy, here we performed the CO 2 immersion after infrainguinal bypass surgery. Methods : This study was designed as a prospective controlled trial. Fifty-five patients with ischemic ulcer/gangrene underwent the standard care including successful infrainguinal bypass surgery were enrolled and were randomly divided into the two groups; patients underwent standard care added CO 2 immersion (CO 2 group, 27 patients with 30 limbs) and patients received standard care alone (control group, 28 patients with 30 limbs). The patients in the CO 2 group immersed their feet in CO 2 enriched water (depth of 20 –30 cm, 37–38°C, duration for 10 minutes) twice a day. Primary endpoint was defined as complete healing of ischemic ulcers. Results : Baseline demographical data, traditional risk factors, surgical procedure, ankle pressure and transcutaneous oxygen pressure (tcPO 2 ) were comparable between the two groups. Rate of the complete ulcer healing after 1-year was much higher in the CO 2 group than in the control group (43.3% vs. 20.0%, HR 2.72, 95%CI 1.03–7.17, p=0.043). Cox multivariate analysis revealed that CO 2 immersion (HR 4.13, 95%CI 1.09 –15.75, p=0.038), diabetes (HR 0.020, 95%CI 0.01–.303, p=0.005) and tcPO 2 (HR 1.04, 95%CI 1.00 –1.09, p=0.050) were independent predictors for complete ulcer healing. In contrast, rates of 1-year mortality, graft patency and limbs salvage showed no significant differences between 2 groups (p=0.55, p=0.47 and p=0.16, respectively). Conclusion : The CO 2 immersion after infrainguinal bypass surgery provided additional benefit for the ulcer healing in CLI patients with ulcer/gangrene.
Toxicokinetic evaluation of a novel anti-tumor agent, Zalypsis® (PM00104), in dogs
Authors: Jainming Yin, Pablo Aviles, Teresa Wright, Maria Jose Guillen, Carl Ly, William Lee, Simon Munt, Carmen Cuevas, Glynn T. Faircloth
Journal: Cancer Research (2006)

3095   Zalypsis® (PM00104) is a new synthetic alkaloid related to Jorumycin and Renieramycins. Preliminary insights into the mechanism of action of Zalypsis® suggested cell cycle changes, DNA binding properties, and transcriptional inhibition. Zalypsis® has demonstrated a significant  in vitro  activity against solid and non-solid tumor cell lines as well as significant  in vivo  activity in several xenografted human cell lines in mice, such as breast and prostate. Our recent efforts have focused on the toxicokinetic evaluation of Zalypsis® to support multi-cycle toxicology studies. The toxicokinetics of Zalypsis® have been investigated in beagle dogs following either intravenous bolus doses or 24-hour infusion. The plasma samples were processed by liquid-liquid extraction and analyzed by a validated LC/MS/MS method. To assess its toxicokinetic profile in dogs, Zalypsis® was administered as two i.v. bolus injections 14 days apart. A separate study was performed as 5 consecutive days of i.v. bolus dosing. The mean maximum plasma concentrations (C max s) and AUCs increased in a dose-proportional manner over the dose range studied (from 0.008 to 0.08 mg/kg for two-cycle study and from 0.004 to 0.032 mg/kg for the QD x 5 study). The exposure was similar in both sexes, indicating no sex-differences. Also, no differences were observed between the first and last dose suggesting the pharmacokinetics of Zalypsis® were time-independent. The toxicokinetics of Zalypsis® have also been studied in dogs following multiple doses (ranging from 0.008 to 0.08 mg/kg) administered as a two-cycle 24-hour i.v. infusion schedule. The C max s were generally observed at the end of the infusion period, and the plasma levels declined rapidly after the infusion was stopped, displaying multiple compartmental kinetics without notable gender differences. Overall, Zalypsis® plasma levels were fairly comparable among different dose cycles and exposures or C max s appeared to increase proportionally over the investigated dose range.No significant Zalypsis® accumulation was observed after multiple doses. In addition, the results from these toxicokinetic studies confirm previous findings that Zalypsis® has moderate to high systemic clearance, a large volume of distribution, a long half-lives, and linear pharmacokinetics.
Abstract 2935: Blood Pressure Variability At Night Predicts Cardiovascular Events In Type 2 Diabetics
Authors: Kazuo Eguchi, Joji Ishikawa, Satoshi Hoshide, Shizukiyo Ishikawa, Thomas G Pickering, Joseph E Schwartz, Kazuyuki Shimada, Kazuomi Kario
Journal: Circulation (2007)

Background It is not known whether BP variability is a risk factor for future incidence of cardiovascular disease (CVD) in type 2 diabetics (DM). Objective To test the hypotheses that short-term BP variability, including the morning BP surge, evaluated by ambulatory BP, predicts risk of incident CVD in DM. Methods Ambulatory BP monitoring was performed in uncomplicated 300 diabetics without BP medications, and they were followed for 54 ± 20 months. Morning BP was defined as the mean BP during the two hours after awaking, and morning BP surge as morning BP minus mean BP during the 1 hour that included the lowest BP at night. Incident CVD was defined as either myocardial infarction, stroke, or sudden cardiac death, and its relationship to different measures of BP variability, including morning BP surge and the standard deviation (SD) of daytime and nighttime BP was investigated. Cox proportional hazard models were used to estimate hazard ratios (HR) and their 95% CI, before and after controlling for age, sex, BMI, current smoking, antihypertensive medication, total cholesterol, serum creatinine, and 24-h SBP. Results The mean age was 67.8±9.6 years, 48% were male, 253 (84%) had a diagnosis of hypertension, and the mean values of the SD of awake SBP/DBP were 18±6/11±4 mmHg, and those of sleep SBP/DBP were 13±5/9±3 mmHg. During follow-up, there were 29 cardiovascular events. In univariable analyses, morning SBP (p=0.001), SD of awake DBP (p=0.002), and SDs of sleep SBP/DBP (both ps&lt;0.01) were positively associated with incident CVD, but the morning surge of SBP/DBP was not. In multivariable analyses, the SDs of sleep SBP (HR=1.08; 95%CI, 1.01–1.16, p&lt;0.05) and sleep DBP (HR=1.16; 1.07–1.26, p&lt;0.001) were independently associated with incident CVD. Morning BP and morning BP surge were not associated with incident CVD. High nighttime variability of SBP and DBP (15.5 and 10.0 mmHg, each 75 percentile of SD) were associated with 1.6 and 3.0 times the risk of incident CVD, compared to individuals at the 25 percentile. Conclusions The hypothesis that morning BP surge is a predictor of CVD was not supported in our diabetic patients. However, BP variability at night appears to predict incident CVD, independent of ambulatory BP level and other traditional risk factors, in type 2 diabetics.
Quality of life (QOL) changes in breast cancer patients participating in an anastrozole secondary prevention trial
Authors: T. Bao, K. Shahverdi, A. L. Blackford, T. Prowell, S. C. Jeter, P. Powers, L. Wright, C. F. Snyder, V. Stearns, K. Visvanathan
Journal: Journal of Clinical Oncology (2008)

1515 Background: Adjuvant aromatase inhibitor (AI) trials have reported a decreased incidence of contralateral breast (CLB) cancer. AIs may be associated with specific changes in QOL parameters but little is known about the mechanism. We hypothesized that 12 months (mos) of adjuvant anastrozole would worsen QOL and that changes in QOL would correlate with changes in circulating estrogens and inflammatory markers. Methods: We collected QOL data at baseline, 3, 6, and 12 mos from a prospective, single-arm study designed to determine the effect of adjuvant anastrozole on CLB density in postmenopausal women with hormone receptor-positive stage 0-III breast cancer who had completed local therapy. QOL was measured by the revised National Surgical Adjuvant Breast and Bowel Project (NSABP) menopausal symptoms questionnaire, Mayo Clinic hot flash diaries, Center for Epidemiological Studies Depression Scale (CES-D), Hospital Anxiety and Depression Scale (HADS), Medical Outcomes Study (MOS) sleep scale, MOS sexual function scale, and EuroQOL survey. Estrogens and inflammatory markers (interleukins 6 and 8 and tumor necrosis factor-alpha) concentrations were measured at 0, 6, and 12 mos. Results: From 3/04 to 9/06, 54 predominantly Caucasian women (mean age: 62.9 yrs, range: 47–79) were enrolled in the study. Musculoskeletal symptoms were greater at all treatment time points compared to baseline. Overall, there was no statistically significant change in QOL from baseline to any of the time points or when stratified by age. Although women with BMI ≥ 30 had greater decreases in estrone, estradiol, and estrone sulfate levels over time compared to women with BMI < 30 (p interactions < 0.001), menopausal symptoms increased over time only for women with BMI < 30 (p interaction < 0.03). Analysis of inflammatory markers is underway and the data will be available at the meeting. Conclusions: No significant change in overall QOL from baseline was detected during 12 months of adjuvant anastrozole. Obese women were less likely to develop menopausal symptoms despite a larger decrease in estrogen levels, suggesting an alternate etiology. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Novartis, Pfizer Oncology